L'AFTD rejoint l'initiative d'accélérateur de diagnostic

ADDF AFTD Logos

In January, AFTD announced it will leverage support from our generous donors to invest $2.5 million in the Accélérateur de diagnostic program, an initiative of the Alzheimer’s Drug Discovery Foundation (ADDF).

L'investissement de l'AFTD sera complété par un $2.5MM supplémentaire du Accélérateur de diagnostic initiative, qui a reçu un financement initial de Bill Gates, co-fondateur ADDF Leonard A. Lauder et d'autres philanthropes. Le résultat sera de $5 millions dédiés au développement de biomarqueurs FTD.

In addition to Gates, supporters of the Accélérateur de diagnostic include Amazon CEO Jeff Bezos and MacKenzie Bezos. Overall, the Accélérateur de diagnostic program will provide nearly $50 million toward more effectively diagnosing all forms of dementia.

A biomarker – such as blood pressure for cardiovascular disease or bloodsugar level for diabetes – provides measurable evidence of underlying disease. Biomarkers are an essential tool for the early diagnosis and effective treatment of many conditions.

“Today there are no biomarkers for FTD,” said ADDF’s Founding Executive Director and Chief Scientific Officer Howard Fillit, M.D. “The $5 million in new FTD research will include awards to fund exploration for new biomarkers that can help accurately diagnose and track the progression of FTD. It will also enable us to add an FTD arm to large validation studies funded by the Accélérateur de diagnostic.”

AFTD has enjoyed a longstanding research partnership with the ADDF, forged through a shared belief that advances in the scientific knowledge base regarding one form of dementia may lead to breakthroughs in other related conditions. AFTD’s most recent investment represents an expansion of the scope of AFTD’s FTD Biomarkers Initiative, launched in 2016.

"Nous savons aujourd'hui que la lutte contre les maladies neurodégénératives sous toutes leurs formes nécessite un effort de collaboration", a déclaré la PDG de l'AFTD, Susan LJ Dickinson, MS, CGC. "L'AFTD a une longue histoire de collaboration de recherche avec l'ADDF, et nous sommes reconnaissants d'unir à nouveau nos forces, en collaboration avec Bill Gates et d'autres généreux bailleurs de fonds.

"Le partenariat entre l'ADDF et l'AFTD peut s'étendre en fonction des opportunités émergentes alors que nous continuons à poursuivre nos missions organisationnelles", a-t-elle ajouté.

Dans un article de blog published on April 2, Gates announced a request for proposals for the development of a digital biomarker for Alzheimer’s and related dementias. Digital biomarkers, according to the Site Internet de l'ADDF, are “objective, quantifiable physiological and behavioral data that are collected, measured and analyzed by means of digital devices such as portables, wearables, or ambient sensors.”

Interested researchers are asked to submit letters of intent by June 7, with invited full proposals due on August 16. Cliquez ici pour plus d'informations.

Rester informé

color-icon-laptop

Inscrivez-vous maintenant et restez au courant des dernières nouvelles avec notre newsletter, des alertes d'événements, et plus encore…